ClinicalTrials.gg
BiologicalDrugRead study by study

Raludotatug deruxtecan clinical trials

Also written DS-6000a and MK-5909.

studies test it
11
open now
6
in phase 3
4
first study started
2020
ClinicalTrials.gov finds 10 studies for raludotatug deruxtecan. How that becomes 11 here

Every study that search finds has been read, to see whether and how it gives raludotatug deruxtecan. ClinicalTrials.gov counts as of Nov 16, 2026. How drug pages count

  1. 10Found by its intervention search · See all 10 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 6 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. +1Give it under a name that search misses: a biosimilar’s code or a misspelling
  3. 11Give raludotatug deruxtecan to participants
  4. 11Test it: the count on this site

Get an email when these change. Save the raludotatug deruxtecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

R-DXd
9
Raludotatug Deruxtecan
5

Development codes

DS-6000a
7
MK-5909
4

Studies by the year they started

10 studies that test it; most in 2025 (5); 1 more planned to start later

Studies that test raludotatug deruxtecan, by start year
YearStudies
20201
20211
20241
20255
20262

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
7
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 11 · Other 0

Merck Sharp & Dohme LLC (7) · Daiichi Sankyo (4)

Often tested with

Tested in the same studies.

Ifinatamab deruxtecan (2) · 5-HT3 antagonists (1) · NK1 receptor antagonists (1) · Pembrolizumab/Quavonlimab MK-1308A (1) · Anti-ILT4 Monoclonal Antibody MK-4830 (1) · Favezelimab/Pembrolizumab Formulation (1) · Carboplatin (1) · Anti-PD-1/Anti-VEGF Bispecific Antibody MK-2010 (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test raludotatug deruxtecan.

Studies

Open first, then newest update. How each study uses raludotatug deruxtecan has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 11

Tested on its own · 4 — no other medicine in its arm
Tested with established drugs · 3 — they are given beside it
Tested in a combination · 4 — another drug in the study is under test too

Codes

What other systems call raludotatug deruxtecan · ClinicalTrials.gg INT016128

  • UNII (FDA) BPQ010OFD7RALUDOTATUG DERUXTECANOne source FDA
  • NCI Thesaurus C179214Raludotatug DeruxtecanOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion